PSMA-binding agents and uses thereof

Patent metadata

Field	Value
Publication number	US-9861713-B2
Application number	US-201614987032-A
Country	US
Kind code	B2
Filing date	Jan 4, 2016
Priority date	Aug 1, 2008
Publication date	Jan 9, 2018
Grant date	Jan 9, 2018

Abstract

Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.

First claim

The invention claimed is:

1. A composition comprising a compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The composition of claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, magnesium salt, or quaternary ammonium salt.

3. A kit comprising a packaged pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 1 .

4. A method of imaging one or more cells, organs, or tissues comprising exposing the one or more cells, organs, or tissues to, or administering to a subject, a detectably effective amount of the composition of claim 1 and imaging said one or more cells, organs, or tissues.

5. The method of claim 4 , wherein the one or more tissues comprise a prostate tissue.

6. The method of claim 4 , wherein the one or more tissues comprise a kidney tissue, brain tissue, vascular tissue, tumor tissue, endometrium, schwannoma tissue, or Barrett's esophagus tissue.

7. The method of claim 4 , wherein the one or more cells comprise cancer cells selected from lung cancer cells, renal cancer cells, glioblastoma cells, pancreas cancer cells, bladder cancer cells, sarcoma cells, melanoma cells, breast cancer cells, colon cancer cells, esophageal cancer cells, and stomach cancer cells.

8. The method of claim 7 , wherein the cancer cells express prostate-specific membrane antigen (PSMA) in the neovasculature.

9. The method of claim 4 , wherein the one or more cells comprise prostate cancer cells.

10. The method of claim 4 , wherein the one or more cells comprise germ cells, pheochromocytoma cells, or vascular cells undergoing angiogenesis.

11. A method of treating a tumor comprising administering to a subject a therapeutically effective amount of the composition of claim 1 .

12. The method of claim 11 , wherein the tumor is prostate cancer.

Assignees

• Univ Johns Hopkins

Inventors

• Pomper Martin G
• Mease Ronnie Charles
• Chen Ying

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• C07D213/61

  Halogen atoms or nitro radicals · CPC title

• C07C275/16

  being further substituted by carboxyl groups · CPC title